8-K: Silexion Advances Pan-KRAS Therapy to Phase 2/3 Trials

Silexion Therapeutics Corp. presented an updated corporate overview highlighting positive Phase 2 data for its first-generation KRAS-targeting siRNA and plans for a Phase 2/3 trial for its advanced pan-KRAS silencing therapy, SIL204.

Summary

• Silexion Therapeutics Corp. (NASDAQ: SLXN) is developing RNAi therapeutics to silence cancer-driving KRAS proteins at the gene expression level.
• The first-generation product, siG12DLoder siRNA, completed a Phase 2 proof-of-concept (POC) clinical trial in locally advanced pancreatic cancer (LAPC).
• The Phase 2 POC trial showed a strong trend for a 9.3 months improvement in overall survival (OS) with siG12DLoder plus standard of care (SoC) chemotherapy compared to SoC chemotherapy alone.
• The second-generation product, SIL204, is a pan-KRAS mutation silencing siRNA with significantly improved product stability and delivery, offering broader gene silencing activity.
• Preclinical studies for SIL204 demonstrate pan-KRAS anti-tumor activity in pancreatic, colorectal, and lung cancers, supporting a dual-route administration strategy (intratumoral and subcutaneous).
• A Phase 2/3 clinical trial for SIL204, using an integrated systemic (subcutaneous) and intratumoral administration approach, is planned for Q2 2026.
• The company expects strong intellectual property protection for SIL204 until 2043, with potential extensions up to approximately 2048.
• SIL204 API (Active Pharmaceutical Ingredient) has been manufactured under GMP (Good Manufacturing Practice) and is ready for the Phase 2/3 clinical trial by Q1 2026.

Sentiment

Score: 8

Explanation: The sentiment is positive due to promising Phase 2 clinical data for the first-generation product and strong preclinical results for the second-generation pan-KRAS therapy, SIL204, which is advancing to Phase 2/3 trials. The company addresses a high-unmet-need area with a differentiated approach and has strong IP. However, it remains a development-stage company with inherent risks.

Positives

• First-generation siG12DLoder siRNA demonstrated a strong trend for 9.3 months improvement in overall survival in a Phase 2 POC trial for locally advanced pancreatic cancer (LAPC) patients with KRAS G12D/V mutations.
• LODER treatment led to a robust objective response rate of 56% (10/18 patients) in Cohort 1+2 for LAPC patients with G12D/V mutations, with 67% showing response plus becoming resectable.
• LODER was generally well-tolerated with an acceptable safety profile, and an Independent Drug Safety Monitoring Board (DSMB) found no safety concerns.
• Second-generation SIL204 shows significantly improved product stability and delivery, along with broader pan-KRAS gene silencing activity.
• Preclinical results for SIL204 demonstrate potent anti-tumor activity across pancreatic, colorectal, and lung cancers, supporting its potential in multiple indications.
• SIL204's dual administration strategy (intratumoral for primary tumor, subcutaneous for metastases) is designed to address both localized and metastatic disease.
• In silico analysis indicates SIL204 is highly specific for KRAS mutations with low risk for off-target side effects.
• Strong intellectual property protection is expected for SIL204 until 2043, with potential extensions up to 2048.
• The company has a NASDAQ listing (SLXN) and an experienced management team with late-stage development expertise.

Negatives

• Silexion is a development-stage company with a limited operating history.
• The company has never generated any revenue from product sales and may never be profitable.
• The RNAi therapeutic approach for oncology is unproven and may not lead to marketable products.
• Silexion lacks experience in commercial-level product manufacturing, marketing, and sales.
• Uncertainty exists regarding market receptiveness, insurance coverage, and reimbursement for potential products.
• There is a risk that the company may be unable to attract, develop or retain key personnel.
• The company faces the risk of not succeeding at maintaining its listing on Nasdaq.

Risks

• Silexion is a development-stage company and has a limited operating history on which to assess its business.
• Silexion has never generated any revenue from product sales and may never be profitable.
• The approach Silexion is taking to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.
• Silexion does not have experience producing its product candidates at commercial levels, currently has no marketing and sales organization, has an uncertain market receptiveness to its product candidates, and is uncertain as to whether there will be insurance coverage and reimbursement for its potential products.
• Silexion may be unable to attract, develop and/or retain its key personnel or additional employees required for its development and future success.
• Silexion may not succeed at maintaining its listing on Nasdaq.
• Additional factors relating to the business, operations and financial performance of Silexion could impact results.

Future Outlook

Silexion plans to submit a Clinical Trial Application (CTA) in the E.U. for its Phase 2/3 clinical trial of SIL204 in Q1 2026, with trial initiation in Germany/Israel expected in H1 2026. The company intends to complete Segment 1 of the Phase 2/3 trial (dose selection) and then expand to Segment 2 (randomized, blinded subcutaneous doses). A Pre-IND meeting and subsequent IND submission for expansion of the Phase 2/3 trial to the USA and additional EU regions are also planned. Preclinical work for SIL204 in colorectal cancer and as an adjunct to CPIs (checkpoint inhibitors) plus chemotherapy in KRAS-driven cancers is ongoing.

Management Comments

• Ilan Hadar, Chairman and CEO, leads with over 25 years of multinational executive managerial and corporate experience.
• Dr. Mitchell Shirvan, Chief Scientific and Development Officer, brings over 30 years of experience in R&D, innovation, and discovery in biotech.
• Mirit Horenshtein Hadar, CFO, has over 15 years of corporate finance experience in senior financial positions for public and private companies.

Industry Context

KRAS mutations are highly prevalent cancer drivers, particularly in pancreatic (92%), colorectal (49%), and non-small-cell lung cancers (35%), representing a multi-billion dollar market opportunity. Current KRAS inhibitors target mutated proteins after formation, often facing limitations in side effects, resistance, and efficacy. Silexion's siRNA technology offers a differentiated approach by silencing KRAS expression at the outset, potentially overcoming these limitations and providing a safer, more durable treatment option in a high-unmet-need area like locally advanced pancreatic cancer.

Comparison to Industry Standards

• The median overall survival for non-resectable pancreatic cancer populations is typically 14-17 months. Silexion's first-generation LODER + SoC chemotherapy showed a median overall survival of 22.7 months, compared to 13.4 months for SoC chemotherapy alone in its POC study, representing a 9.3-month improvement. This 13.4-month SoC control OS is consistent with recent trials for LAPC (e.g., Gemenetzis G, et al. Ann Surg. 2019;270(2):340-347).
• The 69% improvement in overall survival and 41% lower risk of death observed with LODER+SoC compared to SoC chemotherapy alone suggests a significant clinical benefit in a disease with very poor prognosis and limited effective treatment options.
• The 30% response rate is a standard benchmark used in solid tumor clinical trials (RECIST v1.1) to determine Objective Response Rates criteria. The LODER trial achieved a 56% response rate (and 67% including resectability) in KRAS G12D/V mutations, indicating strong efficacy relative to this benchmark.

Stakeholder Impact

• **Shareholders:** Potential for significant value creation if SIL204 successfully progresses through clinical trials and gains regulatory approval, given the large market opportunity in KRAS-driven cancers. However, significant risks associated with a development-stage biotech company remain.
• **Patients:** The development of SIL204 offers a potentially safer and more durable treatment option for patients with KRAS-driven cancers, particularly locally advanced pancreatic cancer, which currently has very limited effective therapies and high mortality rates.
• **Healthcare Providers:** If approved, SIL204 could provide a novel therapeutic approach for oncologists treating KRAS-mutated cancers, potentially overcoming limitations of existing KRAS inhibitors.

Next Steps

• Submit Clinical Trial Application (CTA) in the E.U. for Phase 2/3 clinical trial of SIL204 in Q1 2026.
• Initiate Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer in Germany/Israel in H1 2026.
• Complete Segment 1 of the Phase 2/3 trial to select the two best doses.
• Expand to Segment 2 of the Phase 2/3 trial, involving randomized, blinded subcutaneous doses.
• Conduct a Pre-IND meeting with regulatory authorities.
• Submit an Investigational New Drug (IND) application for expansion of the Phase 2/3 trial to the USA and additional EU regions.
• Continue preclinical development of SIL204 for colorectal cancer and as an adjunct to CPIs plus chemotherapy for KRAS-driven cancers.

Key Dates

Recommendation

The positive Phase 2 proof-of-concept data for the first-generation product and the strong preclinical data for the second-generation pan-KRAS therapy, SIL204, represent significant progress and potential. The planned Phase 2/3 trial initiation in H1 2026 is a key future catalyst. However, Silexion is a development-stage company with no revenue, an unproven therapeutic approach in oncology, and faces substantial clinical, regulatory, and commercialization risks. While the long-term potential is considerable, the immediate investment carries high risk, warranting a 'hold' for investors who are already exposed or considering a speculative position, awaiting further clinical de-risking.

Keywords

Silexion Therapeutics, SLXN, RNAi, KRAS, Oncology, Pancreatic Cancer, Colorectal Cancer, Lung Cancer, siRNA, Gene Silencing, LODER, SIL204, Clinical Trial, Biotechnology, Pharmaceuticals, Cancer Treatment